The estimated Net Worth of Theodore Daniel Zucconi is at least $13.9 mil dollars as of 16 April 2018. Theodore Zucconi owns over 4,000 units of Galectin Therapeutics Inc stock worth over $13,927 and over the last 8 years Theodore sold GALT stock worth over $0.
Theodore has made over 2 trades of the Galectin Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Theodore exercised 4,000 units of GALT stock worth $3,560 on 16 April 2018.
The largest trade Theodore's ever made was exercising 4,000 units of Galectin Therapeutics Inc stock on 16 April 2018 worth over $3,560. On average, Theodore trades about 1,000 units every 66 days since 2016. As of 16 April 2018 Theodore still owns at least 5,083 units of Galectin Therapeutics Inc stock.
You can see the complete history of Theodore Zucconi stock trades at the bottom of the page.
Theodore's mailing address filed with the SEC is 4960 Peachtree Industrial Blvd #240, Norcross, GA 30071, USA.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr y Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: